David Rial‐Crestelo

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

Rosa de Miguel Buckley, David Rial‐Crestelo, Lourdes Domínguez et al. · EBioMedicine · 2020 · 37 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Inés Suárez‐García, Belén Alejos, Víctoria Hernando et al. · Journal of Antimicrobial Chemotherapy · 2023 · 34 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

David Rial‐Crestelo, Rosa de Miguel Buckley, Rocío Montejano et al. · Journal of Antimicrobial Chemotherapy · 2020 · 29 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis

Madhusudan Kabra, Tristan Barber, Clotilde Allavena et al. · Open Forum Infectious Diseases · 2023 · 23 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19–Convalescent Individuals

Joanna Luczkowiak, Nuria Labiod, Gonzalo Alonso Rivas et al. · The Journal of Infectious Diseases · 2021 · 20 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +9